Lung cancer patient, advocate, cofounder and president of EGFR Resisters.
Adverse Effect Management in the COCOON Trial for EGFR-Mutated NSCLC: Jill Feldman
Jill Feldman, cofounder and president, EGFR Resisters, shares the importance of being proactive in managing dermatologic toxicities in epidermal growth factor receptor (EGFR)–positive lung cancer.